Relationship between Vitamin D level and Insulin Resistance According to Obesity Level

Abstract

Introduction: Obesity and metabolic syndrome are universal health problems. There is increasing evidence that vitamin D deficiency is a risk factor in the development of insulin resistance(IR). This study was aimed to investigate the relationship between vitamin D level and IR in obese patients. Method: The study included 95 adult, obese patients, without a history of hypertension, diabetes mellitus, and hyperlipidemia. Fasting blood glucose, insulin, 25-OH-vitamin D, and serum lipid levels were measured and the HOMA-IR level was calculated. The patients were divided into 3 groups according to their obesity level. Results: Seventy-eight (82.1%) of patients were female and vitamin D deficiency was found in 77.9% of the patients. The median HOMA-IR level of the group with and without vitamin D deficiency was 3.57, and 2.39, respectively (p = 0.029). There weren't any significant differences in gender, BMI, and vitamin D levels between the groups with /without IR. No difference was found between obesity level groups in terms of age, gender, and vitamin D level. However, while insulin level and IR level increased significantly in morbid obese patients, this relationship could not be demonstrated in super-obese patients. Conclusion: This study is the first study investigating the relationship between vitamin D-HOMA-IR in morbid and super obese patients. No statistically significant linear correlation was found between vitamin D and HOMA-IR level, but vitamin D deficiency was more common in the group with IR. Additional studies are needed to explain the relationship between the level of obesity and the effect of vitamin D on IR.

Keywords

• insulin resistance
• obesity
• vitamin D deficiency
• metabolic syndrome

References

1. World Health Organization. WHO fact sheet on overweight and obesity. Updated October 2017. http://www.who. Int/mediacentre/factsheets/fs311/en/. 16 Feb 2018
2. Buysschaert M, Medina JL, Bergman M, Shah A, Lonier J. Prediabetes and associated disorders. Endocrine. 2015 Mar;48(2):371-93. doi: 10.1007/s12020-014-0436-2.
3. Faerch K, Borch-Johnsen K, Holst JJ, Vaag A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia. 2009 Sep;52(9):1714-23. doi: 10.1007/s00125-009-1443-3.
4. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Executive summary complete guidelines available at https://www.aace.com/publications/guidelines. Endocr Pract. 2016 Jul;22(7):842-84. doi: 10.4158/EP161356.ESGL.
5. Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016 May;26(4):364-73. doi: 10.1016/j.tcm.2015.10.004.
6. Tao S, Yuan Q, Mao L, Chen FL, Ji F, Cui ZH. Vitamin D deficiency causes insulin resistance by provoking oxidative stress in hepatocytes. Oncotarget. 2017 Jun 28;8(40):67605-67613. doi: 10.18632/oncotarget.18754.
7. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004 May;79(5):820-5. doi: 10.1093/ajcn/79.5.820.
8. Tabesh M, Azadbakht L, Faghihimani E, Tabesh M, Esmaillzadeh A. Effects of calcium-vitamin D co-supplementation on metabolic profiles in vitamin D insufficient people with type 2 diabetes: a randomised controlled clinical trial. Diabetologia. 2014 Oct;57(10):2038-47. doi: 10.1007/s00125-014-3313-x.

9. Upreti V, Maitri V, Dhull P, Handa A, Prakash MS, Behl A. Effect of oral vitamin D supplementation on glycemic control in patients with type 2 diabetes mellitus with coexisting hypovitaminosis D: A parellel group placebo controlled randomized controlled pilot study. Diabetes Metab Syndr. 2018 Jul;12(4):509-512. doi: 10.1016/j.dsx.2018.03.008.
10. Mirhosseini N, Vatanparast H, Mazidi M, Kimball SM. The Effect of Improved Serum 25-Hydroxyvitamin D Status on Glycemic Control in Diabetic Patients: A Meta-Analysis. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3097-3110. doi: 10.1210/jc.2017-01024.
11. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia. 1995 Oct;38(10):1239-45. doi: 10.1007/BF00422375.
12. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004 May;79(5):820-5. doi: 10.1093/ajcn/79.5.820.
13. Karatas S, Hekimsoy Z, Dinc G, Onur E, Ozmen B. Vitamin D levels in overweight/obese adults with and without metabolic syndrome. J Endocrinol Metab. 2013;3(3):47-56 doi: https://doi.org/10.4021/jem166e.
14. Clemente-Postigo M, Muñoz-Garach A, Serrano M, Garrido-Sánchez L, Bernal-López MR, Fernández-García D, Moreno-Santos I, Garriga N, Castellano-Castillo D, Camargo A, Fernández-Real JM, Cardona F, Tinahones FJ, Macías-González M. Serum 25-hydroxyvitamin D and adipose tissue vitamin D receptor gene expression: relationship with obesity and type 2 diabetes. J Clin Endocrinol Metab. 2015 Apr;100(4):E591-5. doi: 10.1210/jc.2014-3016.